GT Biopharma, Inc. - FORM 10-K - EX-32.2 - SECTION 1350 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - March 31, 2011

Attached files

file filename
10-K - OXIS INTERNATIONAL 2010 ANNUAL REPORT - GT Biopharma, Inc.annualreport2010.htm
EX-3.2 - CERTIFICATE OF AMENDMENT TO AMENDED & RESTATED CERTIFICATE OF INCORPORATION - GT Biopharma, Inc.ex32.htm
EX-4.7 - 2010 EQUITY INCENTIVE PLAN - GT Biopharma, Inc.ex47.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - GT Biopharma, Inc.ex311.htm
EX-32.1 - SECTION 1350 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - GT Biopharma, Inc.ex321.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - GT Biopharma, Inc.ex312.htm
EX-10.17 - SERIES I PREFERRED STOCK PURCHASE AGREEMENT DATED OCTOBER 13, 2010 - GT Biopharma, Inc.ex1017.htm
EX-10.16 - COMMITMENT LETTER DATED OCTOBER 13, 2010 - GT Biopharma, Inc.ex1016.htm
EX-10.18 - FIRST AMENDMENT TO 0% CONVERTIBLE DEBENTURE DATED DECEMBER 23, 2010 - GT Biopharma, Inc.ex1018.htm
EX-3.4 - CERTIFICATE OF DESIGNATION OF SERIES I CONVERTIBLE PREFERRED STOCK - GT Biopharma, Inc.ex34.htm
Exhibit 32.2
 
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
 
Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Oxis International, Inc. (the “Company”) hereby certifies that, to his knowledge:
 
(i) The Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2010 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 

Date:  March 31, 2011
By:       /s/ MICHAEL HANDELMAN                                                              
Name:  Michael Handelman
Title:    Chief Financial Officer and Treasurer
 

 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 

Stock widget

Investing forum

GT Biopharma, Inc. Reports